Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burcu Aslan

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Blood Advances|November 10, 2022
Curing CLL: one clone at a timeBurcu Aslan, Shady I Tantawy, Varsha Gandhi
Methods in Molecular Biology (Clifton, N.J.)|October 24, 2018
Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia CellsBurcu Aslan, Mary L Ayres, Varsha Gandhi
Journal of Drug Targeting|October 2, 2013
Nanotechnology in cancer therapyBurcu Aslan, Bulent Ozpolat, Anil K Sood, et al.
World Journal of Gastroenterology|November 22, 2013
Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?Mustafa Cengiz, Burcu Aslan Candır, Güldal Yılmaz, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|May 13, 2026
Defibrotide-Responsive Cutaneous Endothelial Injury Following Allogeneic Hematopoietic Stem Cell Transplant: A Case ReportBurcu Aslan Candir, Bahar Ulu Uncu, Kubra Citlak, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 12, 2022
Skin ulcers caused by ruxolitinib in a patient with chronic cutaneous graft-versus-host diseaseBurcu Aslan Candır, Tuğçe Nur Yiğenoğlu, Merih Kızıl Çakar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 10, 2022
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbiditiesBurcu Aslan Candır, Tuğçe Nur Yiğenoğlu, Merih Kızıl Çakar, et al.
Haematologica|September 9, 2021
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinaseBurcu Aslan, Stefan Edward Hubner, Judith A Fox, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 22, 2017
Chitosan Nanoparticles for miRNA DeliveryMerve Denizli, Burcu Aslan, Lingegowda S Mangala, et al.
Blood Advances|July 5, 2024
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinibBurcu Aslan, Ganiraju Manyam, Lakesla R Iles, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Blood Advances|November 10, 2022
Curing CLL: one clone at a timeBurcu Aslan, Shady I Tantawy, Varsha Gandhi
Methods in Molecular Biology (Clifton, N.J.)|October 24, 2018
Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia CellsBurcu Aslan, Mary L Ayres, Varsha Gandhi
Journal of Drug Targeting|October 2, 2013
Nanotechnology in cancer therapyBurcu Aslan, Bulent Ozpolat, Anil K Sood, et al.
World Journal of Gastroenterology|November 22, 2013
Is increased red cell distribution width an indicating marker of nonalcoholic steatohepatitis and fibrotic stage?Mustafa Cengiz, Burcu Aslan Candır, Güldal Yılmaz, et al.
Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation|May 13, 2026
Defibrotide-Responsive Cutaneous Endothelial Injury Following Allogeneic Hematopoietic Stem Cell Transplant: A Case ReportBurcu Aslan Candir, Bahar Ulu Uncu, Kubra Citlak, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 12, 2022
Skin ulcers caused by ruxolitinib in a patient with chronic cutaneous graft-versus-host diseaseBurcu Aslan Candır, Tuğçe Nur Yiğenoğlu, Merih Kızıl Çakar, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 10, 2022
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbiditiesBurcu Aslan Candır, Tuğçe Nur Yiğenoğlu, Merih Kızıl Çakar, et al.
Haematologica|September 9, 2021
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinaseBurcu Aslan, Stefan Edward Hubner, Judith A Fox, et al.
Methods in Molecular Biology (Clifton, N.J.)|July 22, 2017
Chitosan Nanoparticles for miRNA DeliveryMerve Denizli, Burcu Aslan, Lingegowda S Mangala, et al.
Blood Advances|July 5, 2024
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinibBurcu Aslan, Ganiraju Manyam, Lakesla R Iles, et al.
Pageof 4